Form 4: Oscar Health CTO Sells Shares Under 10b5-1 Plan

Oscar Health's President of Technology and CTO, Mario Schlosser, sold 23,038 shares of Class A Common Stock for $17.65 per share under a pre-arranged trading plan.

Summary

• Mario Schlosser, Oscar Health's Director, President of Technology & CTO, executed a transaction on January 8, 2026.
• The transaction involved the conversion of 23,038 shares of Class B Common Stock into Class A Common Stock.
• Immediately following the conversion, 23,038 shares of Class A Common Stock were sold at a price of $17.65 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Mario Schlosser directly beneficially owns 350,180 shares of Class A Common Stock and 1,409,255 shares of Class B Common Stock (after conversion of 23,038 shares).
• Indirect beneficial ownership of Class B Common Stock through various trusts remains unchanged at 1,300,000 shares, with Mr. Schlosser disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The transaction represents a reduction in direct insider ownership, which can be viewed with slight caution, but the execution under a pre-established 10b5-1 plan suggests it is a planned liquidity event rather than a reaction to new negative information.

Negatives

• Mario Schlosser, President of Technology & CTO, reduced his direct beneficial ownership of Class A Common Stock by 23,038 shares.

Future Outlook

NA

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, though the pre-arranged nature of the sale under a 10b5-1 plan reduces the likelihood of a significant negative impact.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-established 10b5-1 trading plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a lack of confidence from the executive. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Oscar Health, OSCR, Form 4, insider trading, stock sale, Mario Schlosser, 10b5-1 plan, Class A Common Stock, Class B Common Stock